TheStreet reissued their buy rating on shares of Biogen Idec (NASDAQ: BIIB) in a report released on Tuesday.
“Biogen Idec (BIIB) has been reiterated by TheStreet Ratings as a buy with a ratings score of A . The company’s strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”
,” the firm’s analyst commented.
Shares of Biogen Idec (NASDAQ: BIIB) traded down 0.04% during mid-day trading on Tuesday, hitting $178.02. Biogen Idec has a one year low of $118.52 and a one year high of $178.41. The stock’s 50-day moving average is currently $166.6. The company has a market cap of $42.068 billion and a P/E ratio of 30.92.
Several other analysts have also recently commented on the stock. Analysts at Morgan Stanley raised their price target on shares of Biogen Idec from $170.00 to $177.00 in a research note to investors on Monday, March 11th. Finally, analysts at Bank of America raised their EPS on shares of Biogen Idec in a research note to investors on Thursday, February 28th. They now have a neutral rating and a $177.00 price target on the stock.
Eleven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Biogen Idec currently has an average rating of Buy and a consensus target price of $169.53.
Biogen Idec Inc. (NASDAQ: BIIB) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.